Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference

IONS 01.08.2025

SERA-AI Powered Highlights
Date of Upcoming Event:2025-01-15
Name of Upcoming Event:43rd Annual J.P. Morgan Healthcare Conference
Full Press ReleaseSEC FilingsOur IONS Tweets

About Gravity Analytica

Recent News

    Recent Filings

    • 01.17.2025 - 4 Statement of changes in beneficial ownership of securities
    • 01.16.2025 - 144 Report of proposed sale of securities

    CARLSBAD, Calif.,Jan. 8, 2025/PRNewswire/ --Ionis Pharmaceuticals, Inc.(Nasdaq: IONS) today announced thatBrett P. Monia, Ph.D., chief executive officer, will present a company overview at the 43rdAnnualJ.P. Morgan Healthcare Conferenceat10:30 a.m. PTonWednesday, January 15, 2025.

    Ionis logo (PRNewsfoto/Ionis Pharmaceuticals, Inc.)

    A live webcast of the presentation can be accessed on the Investors & Media section of the Ionis website athttps://ir.ionis.com/events. A replay will be available on the Ionis website within 48 hours and will be archived for a limited time.

    AboutIonis Pharmaceuticals, Inc.For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients.

    To learn more about Ionis, visitIonis.comand follow us onX (Twitter)andLinkedIn.

    Ionis Investor Contact:D. Wade Walke, Ph.D.,ir@ionis.com– 760-603-2331Ionis Media Contact:Hayley Soffer,media@ionis.com– 760-603-4679

    CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/ionis-to-present-at-43rd-annual-jp-morgan-healthcare-conference-302346348.html

    SOURCEIonis Pharmaceuticals, Inc.

    Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com